Targeting intestinal inflammation with CD98 siRNA/PEI-loaded nanoparticles

Molecular Therapy

Volumn 22, Issue 1, 2014, Pages 69-80

  Laroui, Hamed ^a   Geem, Duke ^b   Xiao, Bo ^a   Viennois, Emilie ^a   Rakhya, Poonam ^a   Denning, Timothy ^b   Merlin, Didier ^a,c  

^a GEORGIA STATE UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD98 ANTIGEN; FLUORESCEIN ISOTHIOCYANATE; NANOPARTICLE; POLYETHYLENEIMINE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CELL VIABILITY; COLITIS; COMPLEX FORMATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEGRADATION KINETICS; DENDRITIC CELL; DOWN REGULATION; DRUG EFFECT; ENTERITIS; FLOW CYTOMETRY; INTESTINE CELL; INTESTINE EPITHELIUM CELL; MACROPHAGE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; PHYSICAL CHEMISTRY; ZETA POTENTIAL;

MUS;

ANIMALS; ANTIGENS, CD98; CELL LINE; CELL SURVIVAL; COLON; DENDRITIC CELLS; DEXTRAN SULFATE; GENE TRANSFER TECHNIQUES; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; INTESTINES; MACROPHAGES; MICE; NANOPARTICLES; POLYETHYLENEIMINE; RNA, SMALL INTERFERING;

EID: 84891830156     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.214     Document Type: Article

References (50)

1. Toruner, M, Loftus, EV Jr, Harmsen, WS, Zinsmeister, AR, Orenstein, R, Sandborn, WJ et al. (2008). Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134: 929-936
2. Dignass, A, Van Assche, G, Lindsay, JO, Lémann, M, Söderholm, J, Colombel, JF et al.; European Crohn's and Colitis Organisation (ECCO). (2010). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 4: 28-62
3. Xue, FM, Zhang, HP, Hao, HJ, Shi, ZY, Zhou, C, Feng, B et al. (2012). CD98 positive eosinophils contribute to T helper 1 pattern inflammation. PLoS ONE 7: E51830
4. Nguyen, HT, Dalmasso, G, Torkvist, L, Halfvarson, J, Yan, Y, Laroui, H et al. (2011). CD98 expression modulates intestinal homeostasis, inflammation, and colitisassociated cancer in mice. J Clin Invest 121: 1733-1747
5. Feral, CC, Nishiya, N, Fenczik, CA, Stuhlmann, H, Slepak, M and Ginsberg, MH (2005). CD98hc (SLC3A2) mediates integrin signaling. Proc Natl Acad Sci USA 102: 355-360
6. Prager, GW, Féral, CC, Kim, C, Han, J and Ginsberg, MH (2007). CD98hc (SLC3A2) interaction with the integrin beta subunit cytoplasmic domain mediates adhesive signaling. J Biol Chem 282: 24477-24484
7. Fais, S and Pallone, F (1989). Ability of human colonic epithelium to express the 4F2 antigen, the common acute lymphoblastic leukemia antigen, and the transferrin receptor. Studies in inflammatory bowel disease and after in vitro exposure to different stimuli. Gastroenterology 97: 1435-1441
8. Yan, Y, Dalmasso, G, Sitaraman, S and Merlin, D (2007). Characterization of the human intestinal CD98 promoter and its regulation by interferon-gamma. Am J Physiol Gastrointest Liver Physiol 292: G535-G545
9. Nguyen, HT, Dalmasso, G, Yan, Y, Laroui, H, Dahan, S, Mayer, L et al. (2010). MicroRNA-7 modulates CD98 expression during intestinal epithelial cell differentiation. J Biol Chem 285: 1479-1489
10. Tsumura, H, Ito, M, Li, XK, Nakamura, A, Ohnami, N, Fujimoto, J et al. (2012). The role of CD98hc in mouse macrophage functions. Cell Immunol 276: 128-134
11. Kucharzik, T, Lugering, A, Yan, Y, Driss, A, Charrier, L, Sitaraman, S et al. (2005). Activation of epithelial CD98 glycoprotein perpetuates colonic inflammation. Lab Invest 85: 932-941
12. Lieberman, J, Song, E, Lee, SK and Shankar, P (2003). Interfering with disease: Opportunities and roadblocks to harnessing RNA interference. Trends Mol Med 9: 397-403
13. Meade, BR and Dowdy, SF (2007). Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv Drug Deliv Rev 59: 134-140
14. Kim, B, Tang, Q, Biswas, PS, Xu, J, Schiffelers, RM, Xie, FY et al. (2004). Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: Therapeutic strategy for herpetic stromal keratitis. Am J Pathol 165: 2177-2185
15. Pardridge, WM (2004). Intravenous, non-viral RNAi gene therapy of brain cancer. Expert Opin Biol Ther 4: 1103-1113
16. Toub, N, Bertrand, JR, Tamaddon, A, Elhamess, H, Hillaireau, H, Maksimenko, A et al. (2006). Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma. Pharm Res 23: 892-900
17. Fattal, E, Vauthier, C, Aynie, I, Nakada, Y, Lambert, G, Malvy, C et al. (1998). Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides. J Control Release 53: 137-143
18. Laroui, H, Theiss, AL, Yan, Y, Dalmasso, G, Nguyen, HT, Sitaraman, SV et al. (2011). Functional TNFa gene silencing mediated by polyethyleneimine/TNFa siRNA nanocomplexes in inflamed colon. Biomaterials 32: 1218-1228
19. Lamprecht, A, Schäfer, U and Lehr, CM (2001). Size-dependent bioadhesion of microand nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res 18: 788-793
20. Mao, S, Neu, M, Germershaus, O, Merkel, O, Sitterberg, J, Bakowsky, U et al. (2006). Influence of polyethylene glycol chain length on the physicochemical and biological properties of poly(ethylene imine)-graft-poly(ethylene glycol) block copolymer/SiRNA polyplexes. Bioconjug Chem 17: 1209-1218
21. Jere, D, Jiang, HL, Arote, R, Kim, YK, Choi, YJ, Cho, MH et al. (2009). Degradable polyethylenimines as DNA and small interfering RNA carriers. Expert Opin Drug Deliv 6: 827-834
22. Abbasi, S, Paul, A and Prakash, S (2011). Investigation of siRNA-loaded polyethylenimine-coated human serum albumin nanoparticle complexes for the treatment of breast cancer. Cell Biochem Biophys 61: 277-287
23. Höbel, S, Prinz, R, Malek, A, Urban-Klein, B, Sitterberg, J, Bakowsky, U et al. (2008). Polyethylenimine PEI F25-LMW allows the long-term storage of frozen complexes as fully active reagents in siRNA-mediated gene targeting and DNA delivery. Eur J Pharm Biopharm 70: 29-41
24. Charrier, L, Yan, Y, Driss, A, Laboisse, CL, Sitaraman, SV and Merlin, D (2005). ADAM- 15 inhibits wound healing in human intestinal epithelial cell monolayers. Am J Physiol Gastrointest Liver Physiol 288: G346-G353
25. Charrier, L, Yan, Y, Nguyen, HT, Dalmasso, G, Laboisse, CL, Gewirtz, AT et al. (2007). ADAM-15/metargidin mediates homotypic aggregation of human T lymphocytes and heterotypic interactions of T lymphocytes with intestinal epithelial cells. J Biol Chem 282: 16948-16958
26. Maruyama, K, Iwasaki, F, Takizawa, T, Yanagie, H, Niidome, T, Yamada, E et al. (2004). Novel receptor-mediated gene delivery system comprising plasmid/ protamine/sugar-containing polyanion ternary complex. Biomaterials 25: 3267-3273
27. Akinc, A, Thomas, M, Klibanov, AM and Langer, R (2005). Exploring polyethyleniminemediated DNA transfection and the proton sponge hypothesis. J Gene Med 7: 657-663
28. Laroui, H, Dalmasso, G, Nguyen, HT, Yan, Y, Sitaraman, SV and Merlin, D (2010). Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology 138: 843-53.e1
29. Yan, Y, Kolachala, V, Dalmasso, G, Nguyen, H, Laroui, H, Sitaraman, SV et al. (2009). Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis. PLoS ONE 4: E6073
30. Cooper, HS, Murthy, SN, Shah, RS and Sedergran, DJ (1993). Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69: 238-249
31. Stallmach, A, Hagel, S and Bruns, T (2010). Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol 24: 167-182
32. Nguyen, HT, Dalmasso, G, Yan, Y, Laroui, H, Charania, M, Ingersoll, S et al. (2012). Intestinal epithelial cell-specific CD98 expression regulates tumorigenesis in Apc(Min/+) mice. Lab Invest 92: 1203-1212
33. Charania, MA, Ayyadurai, S, Ingersoll, SA, Xiao, B, Viennois, E, Yan, Y et al. (2012). Intestinal epithelial CD98 synthesis specifically modulates expression of colonic microRNAs during colitis. Am J Physiol Gastrointest Liver Physiol 302: G1282- G1291
34. deShazo, RD and Kemp, SF (1997). Allergic reactions to drugs and biologic agents. JAMA 278: 1895-1906
35. Riedl, MA and Casillas, AM (2003). Adverse drug reactions: Types and treatment options. Am Fam Physician 68: 1781-1790
36. Tiemi, J, Komati, S and Sdepanian, VL (2010). Effectiveness of infliximab in Brazilian children and adolescents with Crohn disease and ulcerative colitis according to clinical manifestations, activity indices of inflammatory bowel disease, and corticosteroid use. J Pediatr Gastroenterol Nutr 50: 628-633
37. Tursi, A, Elisei, W, Brandimarte, G, Giorgetti, G, Penna, A and Castrignano, V (2010). Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice. Eur Rev Med Pharmacol Sci 14: 47-55
38. Miele, E, Markowitz, JE, Mamula, P and Baldassano, RN (2004). Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 38: 502-508
39. Schneeweiss, S, Korzenik, J, Solomon, DH, Canning, C, Lee, J and Bressler, B (2009). Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 30: 253-264
40. Biancone, L, Petruzziello, C, Orlando, A, Kohn, A, Ardizzone, S, Daperno, M et al. (2011). Cancer in Crohn's Disease patients treated with infliximab: A long-term multicenter matched pair study. Inflamm Bowel Dis 17: 758-766
41. Iborra, M, Beltrán, B, Bastida, G, Aguas, M and Nos, P (2011). Infliximab and adalimumab-induced psoriasis in Crohn's disease: A paradoxical side effect. J Crohns Colitis 5: 157-161
42. Wachsmann, P and Lamprecht, A (2012). Polymeric nanoparticles for the selective therapy of inflammatory bowel disease. Meth Enzymol 508: 377-397
43. Namba, K, Nishio, M, Mori, K, Miyamoto, N, Tsurudome, M, Ito, M et al. (2001). Involvement of ADAM9 in multinucleated giant cell formation of blood monocytes. Cell Immunol 213: 104-113
44. Helming, L and Gordon, S (2007). The molecular basis of macrophage fusion. Immunobiology 212: 785-793
45. MacLauchlan, S, Skokos, EA, Meznarich, N, Zhu, DH, Raoof, S, Shipley, JM et al. (2009). Macrophage fusion, giant cell formation, and the foreign body response require matrix metalloproteinase 9. J Leukoc Biol 85: 617-626
46. Ferrés-Coy, A, Pilar-Cuellar, F, Vidal, R, Paz, V, Masana, M, Cortés, R et al. (2013). RNAi-mediated serotonin transporter suppression rapidly increases serotonergic neurotransmission and hippocampal neurogenesis. Transl Psychiatry 3: E211
47. Li, L, Wang, R, Wilcox, D, Zhao, X, Song, J, Lin, X et al. (2012). Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery. Gene Ther 19: 775-780
48. Ngamwongsatit, P, Banada, PP, Panbangred, W and Bhunia, AK (2008). WST- 1-based cell cytotoxicity assay as a substitute for MTT-based assay for rapid detection of toxigenic Bacillus species using CHO cell line. J Microbiol Methods 73: 211-215
49. Pizarro, TT, Arseneau, KO, Bamias, G and Cominelli, F (2003). Mouse models for the study of Crohn's disease. Trends Mol Med 9: 218-222
50. Viennois, E, Chen, F, Laroui, H, Baker, MT and Merlin, D (2013). Dextran sodium sulfate inhibits the activities of both polymerase and reverse transcriptase: Lithium chloride purification, a rapid and efficient technique to purify RNA. BMC Res Notes 6: 360